Adverse effects of amoxicillin may be potentially under-reported
the ONA take:
Amoxicillin is a widely used antibiotic in the penicillin group of drugs. It is used to treat bacterial infections in patients with cancer, and may be used as prophylaxis in some patients. In a systematic review, researchers conducted a review of controlled trials to assess potential harms related to amoxicillin use.
The review included a total of 45 trials, featuring a total of 10,519 participants. The researchers found that almost twice as many patients receiving amoxicillin had diarrhea compared with patients receiving placebo, and diarrhea was more than three times more likely among participants receiving amoxicillin-clavulanate. An association between candidiasis and amoxicillin-clavulanic acid use was also observed.
However, the authors acknowledge a limitation to their study. All the trials measured efficacy rather than harm as their primary outcome, and only 25 of the study included information on harms. Therefore, the number of harms reported was lower than expected, which contributed to a conclusion that harms may be under-reported in clinical trials. In a related commentary, clinicians are advised to be wary of the lack of information on potential adverse effects from amoxicillin.
Researchers conducted a review of controlled trials to assess potential harms related to amoxicillin use.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|